For the better part of a decade, Donald Trump has tantalizingly dangled the promise of revealing his healthcare plan just two weeks away. Yet here we are, still waiting.
His recent agreements with pharmaceutical companies offer a glimpse into Trump’s perspective on how healthcare should be structured in the United States.
PoliticusUSA maintains its independence from any political party or special interest group. Support our work by subscribing.
While mainstream media touted Trump’s latest deal as a breakthrough in reducing the cost of weight loss medications, they conveniently overlooked some critical details. For starters, the price tag remains a hefty $149 per month. This figure applies solely to the lowest dose in pill form; opting for injectable versions or higher doses is an entirely different—and more expensive—story.
Trump’s strategy seems to hinge on the assumption that Americans have an extra $149 lying around each month for weight loss treatments, and that they will only require the least expensive option. This is a classic case of overlooking the fine print. Most notably, this initiative is limited to just two manufacturers and participation is entirely voluntary.
The recent announcement regarding weight loss drugs starkly illustrates Trump’s belief that healthcare is not a universal right; rather, the quality of care one receives is directly proportional to their wealth. In essence, his vision appears to advocate a regression to the pre-Obamacare era—where access to healthcare was often a luxury rather than a necessity.
Such proposals, if implemented, could prove detrimental to the American populace.
Explore Trump’s concerning proposal below.
